CTOs on the Move

ZIOPHARM Oncology

www.ziopharm.com

 
ZIOPHARM Oncology is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.ziopharm.com
  • 1180 Avenue Of The Americas
    New York, NY USA 10036
  • Phone: 646.214.0700

Executives

Name Title Contact Details

Similar Companies

Liquidia Technologies

Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.

BioTechniques

BioTechniques is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angion

Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.

JMA

JMA is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virtual Radiologic Corporation

Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in patient care. vRad’s more than 400 radiologists serve 2,000+ facilities, reading 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment.